Appeals
Buy credits Appeal a denial
How it works Pricing For billing companies About Appeal a denial
Field guide · Interventional pain & spine — spinal cord stimulation

Prior auth is here for stimulators.

Since January 1, 2026, CMS’s WISeR model has added prior authorization for spinal cord and nerve stimulators in Original Medicare — in six states to start. The documentation that clears those reviews is the same documentation that wins the appeal.

7-minute read · every figure sourced below · updated July 2026

The prerequisite pathway to a covered permanent implant

NCD 160.7 · LCD L35136 · representative commercial policy
1
Conservative care tried & failed
≥6 months (common)
2
Successful trial
≥50% pain relief
3
Psychological evaluation
multidisciplinary
✓
Covered implant
63650–63688
Skip or under-document any node and the permanent implant denies — even when the trial plainly worked.
What changed in 2026

The WISeR model brought prior auth to fee-for-service Medicare.

CMS’s Wasteful and Inappropriate Service Reduction (WISeR) model has run since January 1, 2026 (through December 31, 2031) and adds prior authorization — or, if you skip it, pre-payment review — to Original Medicare for a defined list of services, with electrical nerve and spinal cord stimulator implants explicitly in scope.1 This is the mechanism covered in our explainer on the WISeR model, and part of a broader shift toward automated payer review.

WISeR — launch states, live since Jan 2026

Window
Jan 1, 2026 – Dec 31, 2031
Program
Original (fee-for-service) Medicare
In scope
Nerve & spinal cord stimulators
Skip PA →
Pre-payment review instead

Six launch states

ArizonaNew JerseyOhioOklahomaTexasWashington

Payment and coverage rules don’t change, and you keep your existing appeal rights. A non-affirmation must be made by a licensed clinician, not an algorithm — which means a documented clinical rebuttal still moves it.

The practical effect: a category of implants that mostly billed straight through now faces an up-front review. Practices that already document the pathway to the policy will clear it; the rest will see denials they used not to.

The pathway

What a covered SCS implant has to show.

Medicare’s national coverage determination for electrical nerve stimulators (NCD 160.7) covers dorsal-column stimulation for chronic intractable pain only after multidisciplinary screening — including psychological evaluation — and a successful trial, with implantation used as a late resort.2 The operative LCD (L35136) makes the trial threshold explicit: a permanent implant is reasonable and necessary when the trial achieved at least 50% reduction in target pain (or analgesic use) and some functional improvement.2 A representative commercial policy adds a minimum 6-month conservative-care trial and psychological clearance before permanent implant.3

The codes themselves span 63650–63688 — 63650 (percutaneous lead) and 63655 (paddle/laminectomy lead) for placement, 63685 for the generator, and the 636xx revisions and removals. The trial is distinguished not by a different code but by the generator remaining external.4

An SCS denial almost never says the stimulator doesn’t work. It says the psych eval, the trial result, or the conservative-care history isn’t in the record the way the policy demands.
The taxonomy

The denial reasons, in the codes you’ll actually see.

Most SCS denials arrive under one of three claim adjustment reason codes. Each maps to a documentation answer, not a clinical argument.

CARCWhat it meansThe usual fix in the appeal
CO-197Precert / authorization absentShow PA on file, or submit the WISeR request with the full packet
CO-50Not deemed medically necessaryTie the trial result and psych eval to NCD 160.7 and the governing LCD
CO-16Missing / incomplete informationSupply the specific missing element (e.g., the 6-month history)

Underneath those codes sit four recurring shortfalls —3 and each is a documentation answer:

i

Conservative care too short

The trial-and-failure history isn’t documented for the full window the policy requires.

ii

Psych eval missing or stale

No multidisciplinary psychological evaluation on file, or one that predates the request.

iii

Trial response not shown

No documented ≥50% relief — the single element a thin denial most often overlooks.

iv

Indication read as off-label

The diagnosis sits outside the plan’s covered list — the subject of section 04.

CARC = Claim Adjustment Reason Code, the standardized denial reason on the 835/EOB (maintained under HIPAA via X12).

Covered vs not

Indication is the other place SCS claims die.

Beyond the pathway, payers draw a hard line on indication. A representative commercial policy covers a defined set and labels the rest experimental — and an off-list indication is a denial regardless of how clean the trial was.3

Commonly covered

  • Failed back surgery syndrome (radicular)
  • CRPS I & II
  • Painful diabetic neuropathy
  • Post-herpetic neuralgia, arachnoiditis
  • Intractable angina; inoperable ischemic limb pain

Often called experimental

  • Cervical SCS for trauma / disc herniation
  • Tremor, migraine, trigeminal neuropathy
  • Chronic pancreatitis
  • Undifferentiated abdominal / pelvic pain

Coverage lists vary by payer and plan; the split above reflects a representative national commercial policy and is illustrative, not universal. For the broader denial pattern across this specialty, see interventional pain denials.

The arithmetic

High-dollar implants, and an appeal rate near zero.

SCS is among the highest-value procedures an interventional pain practice bills — which makes the prevailing appeals behavior expensive. The professional societies back the standard pathway the policies demand: the NANS/NACC consensus committee and ASIPP both center patient selection on a successful trial with ≥50% relief before permanent implant6 — the exact element a thin denial overlooks.

63650–88

the SCS code family at stake

AMA CPT

11.5%

of Medicare Advantage denials appealed in 2024

KFF · 2024

80.7%

of those appeals were overturned

KFF · 2024

Across Medicare Advantage in 2024, only 11.5% of denials were appealed — while 80.7% of those appeals were overturned.5 On a procedure this expensive, the letters that never got written are the ones that would have paid.
The move

One packet that answers the review — and the appeal.

Merits Appeals assembles the SCS rebuttal from the denial and the chart, mapped to NCD 160.7 and the governing LCD or commercial policy — every clinical detail verified verbatim. The same structured packet that satisfies a WISeR prior-authorization review is the one that overturns a denial after the fact.

What goes in the packet

  • The conservative-care history, documented across the required window
  • The ≥50%-relief trial result, tied to the LCD threshold
  • The psychological evaluation, current and multidisciplinary
  • The indication mapped to the payer’s covered list, with authority cited verbatim

Your team reviews and signs; the labor that used to make small or borderline appeals not worth filing goes away.

See it in action

See it on an SCS denial you’d recognize.

A short look at how Merits drafts a spinal-cord-stimulator appeal, end to end — the pathway, the codes, the cited authority.

Appeal a denial →

Cited letters · the provider reviews and signs · unwinnable denials flagged free

Sources

  1. CMS Innovation Center, WISeR Model (Jan 1, 2026–Dec 31, 2031; six states; nerve/spinal-cord stimulators in scope) — summarized by ASRA (Oct 2025) and Katten.
  2. CMS, NCD 160.7 — Electrical Nerve Stimulators; LCD L35136 — Spinal Cord Stimulators for Chronic Pain (psychological evaluation; ≥50% trial relief plus functional improvement).
  3. Aetna, Clinical Policy Bulletin 0194 — Spinal Cord Stimulation (6-month conservative-care minimum; ≥50% trial; psychological clearance; covered vs experimental indications).
  4. CPT coding 63650–63688 per AAPC; trial vs. permanent distinction per CMS billing article A57709.
  5. KFF, Medicare Advantage prior-authorization appeals & overturns, 2024.
  6. NANS / NACC neuromodulation consensus, Neuromodulation: Technology at the Neural Interface; ASIPP guidelines (≥50% trial relief before permanent implant), summary.